CN100398106C - Nk-1受体拮抗剂对抗良性前列腺增生的用途 - Google Patents

Nk-1受体拮抗剂对抗良性前列腺增生的用途 Download PDF

Info

Publication number
CN100398106C
CN100398106C CNB028087305A CN02808730A CN100398106C CN 100398106 C CN100398106 C CN 100398106C CN B028087305 A CNB028087305 A CN B028087305A CN 02808730 A CN02808730 A CN 02808730A CN 100398106 C CN100398106 C CN 100398106C
Authority
CN
China
Prior art keywords
methyl
phenyl
trifluoromethyl
tolyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028087305A
Other languages
English (en)
Chinese (zh)
Other versions
CN1503684A (zh
Inventor
S·布塞尔
A·P·D·W·福特
T·霍夫曼
B·伦茨
A·J·斯莱特
P·万肯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1503684A publication Critical patent/CN1503684A/zh
Application granted granted Critical
Publication of CN100398106C publication Critical patent/CN100398106C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028087305A 2001-04-23 2002-02-02 Nk-1受体拮抗剂对抗良性前列腺增生的用途 Expired - Lifetime CN100398106C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109853 2001-04-23
EP01109853.0 2001-04-23

Publications (2)

Publication Number Publication Date
CN1503684A CN1503684A (zh) 2004-06-09
CN100398106C true CN100398106C (zh) 2008-07-02

Family

ID=8177209

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028087305A Expired - Lifetime CN100398106C (zh) 2001-04-23 2002-02-02 Nk-1受体拮抗剂对抗良性前列腺增生的用途

Country Status (17)

Country Link
US (1) US20030004157A1 (https=)
EP (1) EP1385577B1 (https=)
JP (1) JP4146730B2 (https=)
KR (1) KR100599134B1 (https=)
CN (1) CN100398106C (https=)
AR (1) AR035935A1 (https=)
AT (1) ATE323531T1 (https=)
AU (1) AU2002250876B2 (https=)
BR (1) BR0209151A (https=)
CA (1) CA2444395C (https=)
DE (1) DE60210760T2 (https=)
DK (1) DK1385577T3 (https=)
ES (1) ES2261657T3 (https=)
MX (1) MXPA03009720A (https=)
PT (1) PT1385577E (https=)
WO (1) WO2002085458A2 (https=)
ZA (1) ZA200308110B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002259147A1 (en) * 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
ATE366576T1 (de) * 2003-01-31 2007-08-15 Hoffmann La Roche Neue kristallmodifikation von 2-(3,5-bis- trifluormethyl-phenyl)-n-6-(1,1-dioxo-1lamda-6-
SI1643998T1 (sl) * 2003-07-03 2007-12-31 Hoffmann La Roche Dvojni nk1/nk3 antagonisti za zdravljenje shizofrenije
ES2246687B2 (es) * 2004-02-11 2006-11-16 Miguel Muñoz Saez Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
GB0808747D0 (en) 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2010106988A1 (ja) 2009-03-17 2010-09-23 第一三共株式会社 アミド誘導体
WO2010119347A1 (en) * 2009-04-14 2010-10-21 Helsinn Healthcare S.A. Netupitant for use in treating bladder dysfunction
US20120196901A1 (en) * 2009-10-29 2012-08-02 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
AU2019215801B2 (en) * 2018-02-02 2024-09-19 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Parenteral formulations and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656639A (en) * 1995-01-30 1997-08-12 Sanofi Heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present
CN1265652A (zh) * 1997-08-06 2000-09-06 伊莱利利公司 用作速激肽受体拮抗剂的2－酰基氨基丙胺化合物
CN1270959A (zh) * 1999-02-24 2000-10-25 弗·哈夫曼-拉罗切有限公司 4－苯基－吡啶衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
CN1272842A (zh) * 1997-08-06 2000-11-08 伊莱利利公司 作为速激肽受体拮抗剂的2－酰氨基丙胺类化合物
JPH11322748A (ja) * 1998-03-19 1999-11-24 Takeda Chem Ind Ltd 複素環化合物、その製造法および用途
WO2000067742A2 (en) * 1999-05-05 2000-11-16 Warner-Lambert Company Use of gaba analogues for the modulation of substance p
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
US6849624B2 (en) * 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656639A (en) * 1995-01-30 1997-08-12 Sanofi Heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present
US5859029A (en) * 1995-01-30 1999-01-12 Sanofi Heterocyclic compounds method of preparing them and pharmeutical compositions in which they are present
CN1265652A (zh) * 1997-08-06 2000-09-06 伊莱利利公司 用作速激肽受体拮抗剂的2－酰基氨基丙胺化合物
CN1270959A (zh) * 1999-02-24 2000-10-25 弗·哈夫曼-拉罗切有限公司 4－苯基－吡啶衍生物

Also Published As

Publication number Publication date
ZA200308110B (en) 2005-03-30
CA2444395C (en) 2010-12-21
WO2002085458A2 (en) 2002-10-31
JP2004529931A (ja) 2004-09-30
AR035935A1 (es) 2004-07-28
JP4146730B2 (ja) 2008-09-10
DE60210760T2 (de) 2006-11-23
MXPA03009720A (es) 2004-01-29
ES2261657T3 (es) 2006-11-16
DK1385577T3 (da) 2006-08-21
CA2444395A1 (en) 2002-10-31
US20030004157A1 (en) 2003-01-02
ATE323531T1 (de) 2006-05-15
PT1385577E (pt) 2006-08-31
DE60210760D1 (de) 2006-05-24
KR100599134B1 (ko) 2006-07-12
BR0209151A (pt) 2004-07-13
CN1503684A (zh) 2004-06-09
EP1385577A2 (en) 2004-02-04
AU2002250876B2 (en) 2005-03-03
KR20040007503A (ko) 2004-01-24
WO2002085458A3 (en) 2003-10-30
EP1385577B1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
CN100398106C (zh) Nk-1受体拮抗剂对抗良性前列腺增生的用途
AU2002250876A1 (en) Use of NK-1 receptor antagonists against benign prostatic hyperplasia
CN107108576B (zh) 作为血浆激肽释放酶抑制剂的n-((杂)芳基甲基)-杂芳基-甲酰胺化合物
CN105324117B (zh) 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物
JP7688078B2 (ja) 遺伝性血管性浮腫の治療
TWI675832B (zh) 新穎的酶抑制劑
JP6762312B2 (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
HUP0401210A2 (hu) NK-1 receptor antagonisták felhasználása agy-, gerinc- vagy idegsérülések kezelésére alkalmas gyógyászati készítmények előállítására
US20140187563A1 (en) Combination therapy in treatment of oncological and fibrotic diseases
US20240360166A1 (en) Salts and solid forms of a compound having glp-1 agonist activity
JP2009504656A (ja) デアセチラーゼ阻害剤の使用法
CN101460197A (zh) 有机化合物的组合
CN102227227A (zh) 包含吡啶并[4，3-d]嘧啶衍生的HSP90抑制剂和HER2抑制剂的药物组合
CN104788423B (zh) 一种新的囊性纤维化跨膜传导调节因子抑制剂
EP1430894A1 (en) Lymphocytic activation inhibitor and remedial agent for autoimmune disease
KR20060130619A (ko) 유기 화합물의 조합물
EP1433479A1 (en) Appetite-stimulating agents and remedies for anorexia
HK40101443A (en) Treatments of hereditary angioedema
HK40070596A (en) Treatments of hereditary angioedema
HK40070596B (en) Treatments of hereditary angioedema
BR122020026459B1 (pt) Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática, seus usos, e composição farmacêutica
MXPA06008295A (en) Combination of organic compounds
WO2010099388A1 (en) Combinational use of a pde3 inhibitor and other agents
AU2009209152A1 (en) A method of administering a PDE3 inhibitor via titration for the treatment of peripheral arterial disease

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20080702